![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
-Lipoic Acid and Cardiovascular Disease1
School of Dietetics and Human Nutrition, McGill University, Ste-Anne-de-Bellevue, Québec, Canada
2To whom correspondence should be addressed. E-mail: jonesp{at}macdonald.mcgill.ca.
-Lipoic acid (ALA) has been identified as a powerful antioxidant found naturally in our diets, but appears to have increased functional capacity when given as a supplement in the form of a natural or synthetic isolate. ALA and its active reduced counterpart, dihydrolipoic acid (DHLA), have been shown to combat oxidative stress by quenching a variety of reactive oxygen species (ROS). Because this molecule is soluble in both aqueous and lipid portions of the cell, its biological functions are not limited solely to one environment. In addition to ROS scavenging, ALA has been shown to be involved in the recycling of other antioxidants in the body including vitamins C and E and glutathione. Not only have the antioxidant qualities of this molecule been studied, but there are also several reports pertaining to its blood lipid modulating characteristics, protection against LDL oxidation and modulation of hypertension. Therefore, ALA represents a possible protective agent against risk factors of cardiovascular disease (CVD). The objective of this review is to examine the literature pertaining to ALA in relation to CVD and describe the most powerful actions and potential uses of this naturally occurring antioxidant. Despite the numerous studies on ALA, many questions remain relating to the use of ALA as a supplement. There is no consensus on dosage, dose frequency, form of administration, and/or preferred form of ALA. However, collectively the literature increases our understanding of the potential uses for supplementation with ALA and identifies key areas for future research.
KEY WORDS: • -lipoic acid • antioxidant • cardiovascular disease
This article has been cited by other articles:
|
|
 |
|
  S.-C. Bae, W.-J. Jung, E.-J. Lee, R. Yu, and M.-K. Sung Effects of Antioxidant Supplements Intervention on the Level of Plasma Inflammatory Molecules and Disease Severity of Rheumatoid Arthritis Patients J. Am. Coll. Nutr., February 1, 2009; 28(1): 56 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Wenzel, U. Hink, M. Oelze, S. Schuppan, K. Schaeuble, S. Schildknecht, K. K. Ho, H. Weiner, M. Bachschmid, T. Munzel, et al. Role of Reduced Lipoic Acid in the Redox Regulation of Mitochondrial Aldehyde Dehydrogenase (ALDH-2) Activity: IMPLICATIONS FOR MITOCHONDRIAL OXIDATIVE STRESS AND NITRATE TOLERANCE J. Biol. Chem., January 5, 2007; 282(1): 792 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ha, J.-H. Lee, H.-N. Kim, H.-M. Kim, H. B. Kwak, S. Lee, H.-H. Kim, and Z. H. Lee {alpha}-Lipoic Acid Inhibits Inflammatory Bone Resorption by Suppressing Prostaglandin E2 Synthesis J. Immunol., January 1, 2006; 176(1): 111 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Ogborne, S. A. Rushworth, and M. A. O'Connell {alpha}-Lipoic Acid-Induced Heme Oxygenase-1 Expression Is Mediated by Nuclear Factor Erythroid 2-Related Factor 2 and p38 Mitogen-Activated Protein Kinase in Human Monocytic Cells Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2100 - 2105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Sen and S. Roy Relief from a heavy heart: redox-sensitive NF-{kappa}B as a therapeutic target in managing cardiac hypertrophy Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H17 - H19. [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. Terjesen, K. Park, M. B. Tesser, M. C. Portella, Y. Zhang, and K. Dabrowski Lipoic Acid and Ascorbic Acid Affect Plasma Free Amino Acids Selectively in the Teleost Fish Pacu (Piaractus mesopotamicus) J. Nutr., November 1, 2004; 134(11): 2930 - 2934. [Abstract] [Full Text] [PDF]
|
|
